Pharmaceutical executives during Tuesday’s Senate Finance Committee hearing mostly dodged key questions, and responded with answers tattered by years of use, according to a STAT report.
While top executives representing Merck, Pfizer, AstraZeneca, Johnson & Johnson, AbbVie, Sanofi and Bristol-Myers Squibb all denied blocking access to drug samples for generic competitors, according to the report, Pfizer and AstraZeneca have in the past been accused of such behavior.
According to the report, committee members and the pharmaceutical representatives were largely respectful with the exception of a handful of exchanges.
Sen. Ron Wyden, top Democrat on the committee, ultimately said after the hearing there remain “no firm commitments” to lower list prices.
To read the full report on STAT, click here.